Published in Anticancer Agents Med Chem on December 01, 2009
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab (2010) 0.95
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol (2005) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther (2008) 1.13
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.09
Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res (2011) 1.06
A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther (2005) 1.04
Treatment options for androgen-independent prostate cancer. Clin Adv Hematol Oncol (2003) 1.00
VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol (2009) 0.99
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.99
Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther (2005) 0.97
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother (2013) 0.95
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther (2003) 0.95
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94
Future directions in tumor immunotherapy: CTLA4 blockade. Nat Clin Pract Oncol (2007) 0.94
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol (2009) 0.93
Anti-angiogenesis approach to genitourinary cancer treatment. Update Cancer Ther (2009) 0.92
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology (2007) 0.91
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther (2003) 0.90
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2008) 0.90
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. J Pharm Sci (2007) 0.89
The role of angiogenesis inhibitors in prostate cancer. Cancer J (2008) 0.89
Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol (2010) 0.87
Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression? Cancer Ther (2007) 0.87
Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother (2010) 0.86
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol (2010) 0.86
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther (2010) 0.86
Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int (2007) 0.86
The use of bisphosphonates in cancer patients. Acta Oncol (2007) 0.85
Hepcidin, anaemia, and prostate cancer. BJU Int (2011) 0.85
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer (2007) 0.85
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int (2008) 0.84
The genetics of castration-resistant prostate cancer: what can the germline tell us? Clin Cancer Res (2008) 0.84
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer (2007) 0.84
Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biol Ther (2004) 0.83
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer (2004) 0.83
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. Am J Ther (2010) 0.82
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. Clin Prostate Cancer (2003) 0.81
Is it time to reevaluate definitive therapy in prostate cancer? J Natl Cancer Inst (2013) 0.81
Reversal of docetaxel resistance with bevacizumab and thalidomide. Clin Genitourin Cancer (2009) 0.81
Novel therapeutic strategies in prostate cancer. Cancer Biol Ther (2004) 0.81
Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opin Emerg Drugs (2014) 0.79
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. Anticancer Drugs (2006) 0.79
Immunotherapy for prostate cancer: what's the future? Hematol Oncol Clin North Am (2006) 0.79
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU Int (2006) 0.79
Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology (2003) 0.79
Chemotherapy for prostate cancer: finally an advance! Am J Ther (2004) 0.78
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. Clin Genitourin Cancer (2013) 0.78
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy (2003) 0.78
Angiogenesis inhibitors in the treatment of prostate cancer. Chem Immunol Allergy (2013) 0.77
Clodronate in the prevention and treatment of skeletal metastasis. Expert Rev Anticancer Ther (2005) 0.77
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer. Rev Urol (2003) 0.77
The use of thalidomide in androgen-independent prostate cancer. Urol Oncol (2006) 0.76
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg (2010) 0.76
Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. Acta Oncol (2008) 0.76
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag (2010) 0.76
Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomark Med (2013) 0.76
Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association? Oncologist (2008) 0.75
Early treatment gets the benefit. J Clin Oncol (2006) 0.75
Tumor angiogenesis as an early marker of long-term prostate cancer mortality. Future Oncol (2010) 0.75
Cabazitaxel: a new drug for metastatic prostate cancer. Asian J Androl (2010) 0.75
Approaches to inhibit invasiveness and metastasis in prostate cancer. Clin Prostate Cancer (2002) 0.75
The emerging role of bisphosphonates in prostate cancer. Am J Ther (2004) 0.75
Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. BJU Int (2007) 0.75
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.75